Oscotec
Oscotec Inc is a South Korean clinical-stage drug discovery company developing targeted small molecule therapeutics for oncology and autoimmune diseases. The company discovers and advances precision biopharmaceuticals, highlighted by its discovery of lazertinib (Leclaza), a third-generation EGFR inhibitor licensed to Yuhan and Janssen for non-small cell lung cancer, alongside developing SYK and AXL/FLT3 kinase inhibitors. Main revenue drivers comprise commercial licensing royalties, research milestone payments, and therapeutic API sales. Oscotec targets global pharmaceutical corporations, medical oncologists, clinical trial centers, and cancer patients across South Korea, North America, and Europe. The company holds an innovative market position as a premier South Korean biotech firm generating blockbuster oncology licensing agreements. Headquartered in Seongnam, Gyeonggi Province, South Korea, it is listed on the KOSDAQ market.
2 of the funds FundTelligence covers report a position in Oscotec.
- Legal name
- OSCOTEC INC
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 2
Funds holding Oscotec
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)